E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Allergy, Peanut |
Alergia, cacahuete |
|
E.1.1.1 | Medical condition in easily understood language |
Peanut allergy |
Alergia al cacahuete |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10034202 |
E.1.2 | Term | Peanut allergy |
E.1.2 | System Organ Class | 100000004870 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of ligelizumab 240 mg and 120 mg (SCq4w) compared to placebo, as measured by the proportion of participants who can tolerate a single dose of ≥ 600 mg (1044 mg cumulative tolerated dose) of peanut protein without dose-limiting symptoms during the Double Blind Placebo Controlled Food Challenge (DBPCFC) at Week 12 |
Evaluar la eficacia de ligelizumab 240 mg y 120 mg (SC c4s), comparado con placebo, según la proporción de participantes que pueden tolerar una dosis única >/=600 mg (dosis acumulada tolerada de 1044 mg) de proteína de cacahuete sin presentar síntomas limitantes de dosis durante la prueba de provocación alimentaria a doble ciego controlada con placebo (PADCCP) en la semana 12. |
|
E.2.2 | Secondary objectives of the trial |
Key: -To evaluate the efficacy of ligelizumab 240mg and 120mg (SCq4w), compared to placebo, as measured by --the proportion of participants who can tolerate a single dose of ≥ 1000mg (2044mg cum. tolerated dose) of peanut protein without dose-limiting symptoms during the DBPCFC at w12 --the proportion of participants who can tolerate a single dose of 3000mg (5044mg cum. tolerated dose) of peanut protein without dose-limiting symptoms during the DBPCFC at w12 --the maximum symptom severity at any single challenge dose up to and including 1000mg of peanut protein during the DBPCFC at w12 -To evaluate the efficacy of 8 weeks of placebo treatment followed by 4 weeks of ligelizumab 120mg and 240mg (SCq4w) treatment compared to 12 weeks of placebo treatment, as measured by the proportion of participants who can tolerate a single dose ≥1000mg of peanut protein without dose-limiting symptoms during the DBPCFC at w12
Other 2ndary objectives: -listed in the clinical study protocol |
Principales: - Evaluar la eficacia de ligelizumab 240 mg y 120 mg (SC c4s), comparado con placebo medido según: -- la proporción de participantes que pueden tolerar una dosis única >/=1000 mg (dosis acumulada tolerada de 2044 mg) de proteína de cacahuete sin presentar síntomas limitantes de dosis durante la PADCCP en la semana 12. -- la proporción de participantes que pueden tolerar una dosis única de 3000 mg (dosis acumulada tolerada de 5044 mg) de proteína de cacahuete sin presentar síntomas limitantes de dosis durante la PADCCP en la semana 12. -- la máxima severidad del síntoma a cualquier dosis única hasta 1000 mg, inclusive, de proteína de cacahuete durante la PADCCP en la semana 12.
Para mas objetivos secundarios, ver protocolo. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Male or female participants who are ≥ 6 and ≤ 55 years of age at the time of signing informed consent/assent. - Documented medical history of allergy to peanuts or peanut-containing foods. - Positive peanut-specific immunoglobulin E (peanut sIgE), ≥ 6 kUA/L at Screening visit 1 (Screening 1) - Positive skin prick test (SPT) for peanut allergen at Screening 1 defined as an average diameter (Longest diameter and mid-point orthogonal diameter) ≥ 4 mm wheal compared to saline control. - A positive peanut DBPCFC at baseline (Screening Visit 2, Part 1 and Part 2 DBPCFC) defined as the occurrence of dose-limiting symptoms at a single dose ≤ 100 mg of peanut protein, and no occurrence on placebo. Eligibility to proceed with the DBPCFC requires fulfillment of all other eligibility criteria. - Participants must weigh ≥ 20 kg at Screening 1.
Other protocol-defined inclusion criteria may apply. |
-Participantes de ambos sexos entre >=/6 y </=55 años de edad en el momento de la firma del consentimiento/asentimiento informado. -Historia clínica documentada de alergia al cacahuete o a alimentos que contienen cacahuete. -Niveles positivos de inmunoglobulina E (IgE) específica del cacahuete >/=6 kUA/l en la visita de selección 1 (selección 1). -Prueba cutánea por punción (PCP) positiva para alérgeno del cacahuete en la selección 1 definida como un diámetro medio (diámetro más largo y diámetro ortogonal en el punto medio) >/=4 mm de la roncha comparado con control de solución salina. -PADCCP con cacahuete positiva en la basal (visita de selección 2, parte 1 y parte 2 de la PADCCP) definida como la aparición de síntomas limitantes de dosis a una dosis única </=100 mg de proteína de cacahuete y ningún síntoma con placebo. Para poder proceder con la PADCCP deben cumplirse todos los demás criterios de elegibilidad. -Los participantes deben pesar >/=20 kg en la selección 1.
Para otros criterios ver protocolo |
|
E.4 | Principal exclusion criteria |
- Total IgE >2000 IU/mL at Screening 1. - History of severe or life-threatening hypersensitivity event needing an ICU admission or intubation within 60 days prior to baseline DBPCFC (Screening visit 2). - Participants with uncontrolled asthma (according to GINA guidelines, GINA 2020) who meet any of the following criteria: - FEV1 <80% of subject’s predicted normal value at Screening visit 1 - One hospitalization for asthma within 12 months prior to Screening visit 1
Other protocol-defined exclusion criteria may apply. |
- IgE total >2000 UI/ml en la selección 1. - Antecedentes de un evento de hipersensibilidad grave o potencialmente mortal que requiera ingreso en la UCI o intubación durante los 60 días anteriores a la PADCCP basal (visita de selección 2). - Participantes con asma no controlada (según las guías GINA 2020) que cumplan alguno de los siguientes criterios: -- FEV1 <80 % del valor teórico normal del paciente en la visita de selección 1. -- Una hospitalización por asma durante los 12 meses anteriores a la visita de selección 1.
Para otros criterios ver protocolo |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Responder status defined as tolerating a single dose of ≥ 600 mg (1044 mg cumulative tolerated dose) of peanut protein without dose-limiting symptoms during the Double Blind Placebo Controlled Food Challenge (DBPCFC) conducted at Week 12 |
Estado de los respondedores definido como tolerar una dosis única >/=600 mg (dosis acumulada tolerada de 1044 mg) de proteína de cacahuete sin presentar síntomas limitantes de dosis durante la prueba de provocación alimentaria a doble ciego controlada con placebo (PADCCP) en la semana 12.. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Key secondary endpoints: - Responder status defined as tolerating a single dose of ≥ 1000 mg (2044 mg cumulative tolerated dose) of peanut protein without dose-limiting symptoms during the DBPCFC conducted at Week 12 - Responder status defined as tolerating a single dose of 3000 mg (5044 mg cumulative tolerated dose) of peanut protein without dose-limiting symptoms during the DBPCFC conducted at Week 12 - Maximum severity of symptoms occurring at any challenge dose of peanut protein up to and including 1000 mg during the DBPCFC conducted at Week 12. Symptom severity will be categorized as 4 levels: None, Mild, Moderate, Severe - Responder status defined as tolerating a single dose of ≥ 1000 mg (2044 mg cumulative tolerated dose) of peanut protein without dose-limiting symptoms during the DBPCFC conducted at Week 12 (8 weeks of placebo + 4 weeks of ligelizumab treatment vs. 12 weeks of placebo)
Other secondary endpoints: - listed in the clinical study protocol |
Las variables secundarias principales son: -Estado de los respondedores definido como tolerar una dosis única >/=1000 mg (dosis acumulada tolerada de 2044 mg) de proteína de cacahuete sin presentar síntomas limitantes de dosis durante la PADCCP en la semana 12. -Estado de los respondedores definido como tolerar una dosis única de 3000 mg (dosis acumulada tolerada de 5044 mg) de proteína de cacahuete sin presentar síntomas limitantes de dosis durante la PADCCP en la semana 12. -Máxima severidad de los síntomas que se presenten con cualquier dosis de proteína de cacahuete hasta 1000 mg, inclusive, durante la PADCCP realizada en la semana 12. La severidad de los síntomas se categorizará en 4 niveles: ninguna, leve, moderada y grave. -Estado de los respondedores definido como que los participantes toleren una dosis única >/=1000 mg (dosis acumulada tolerada de 2044 mg) de proteína de cacahuete sin presentar síntomas limitantes de dosis durante la PADCCP en la semana 12 (8 semanas de placebo + 4 semanas de tratamiento con ligelizumab frente a 12 semanas de placebo).
Otras variables secundarias: -Por favor ver protocolo |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- Week 12 - Week 12 - Week 12 - Week 12
Timepoints of other secondary endpoints are listed in the clinical study protocol. |
-Semana 12 -Semana 12 -Semana 12 -Semana 12
Para mas variables ver protocolo |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Immunogenicity |
Inmunogenicidad |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 5 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 23 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
Japan |
South Africa |
United States |
Denmark |
France |
Germany |
Italy |
Netherlands |
Spain |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Study completion is defined as when the last participant finishes the End of Study visit (Week 68). This includes any repeat assessments associated with this visit with full documentation and follow-up by the Investigator or, in the event of an early study termination decision, the date of that decision. |
La finalización del estudio se define cuando el último participante finaliza la visita de fin del estudio (semana 68). Esto incluye cualquier evaluación repetida asociada con esta visita con la documentación completa y el seguimiento por parte del investigador o, en el caso de una decisión de terminación anticipada del estudio, la fecha de esa decisión. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 11 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 15 |